| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2011 | EP2285398A2 Methods and compositions for the treatment of obesity |
| 02/23/2011 | EP2285393A1 Compositions for the treatment of disorders of the upper respiratory tract and influenza syndroms |
| 02/23/2011 | EP2285388A1 Use of oleuropein and derivatives in the treatment of type 2 diabetes mellitus and pathologies associated with protein aggregation phenomena |
| 02/23/2011 | EP2285387A1 Nutrition for prevention of infections |
| 02/23/2011 | EP2285386A1 Use of ribose in lessening the clinical symptoms of aberrant firing of neurons |
| 02/23/2011 | EP2285385A2 siRNA COMPOUNDS FOR INHIBITING NRF2 |
| 02/23/2011 | EP2285384A2 Boron-containing small molecules |
| 02/23/2011 | EP2285383A2 Sequential administration of 20,20,21,21-pentafluoro-17-hydroxy-11 -ý4-(hydroxyacetyl) phenyl¨-19-nor-17 -pregna-4,9-diene-3-one and one or more progestational hormones for treating gynaecological diseases |
| 02/23/2011 | EP2285382A2 Steroidal compounds as melanogenesis modifiers and uses thereof |
| 02/23/2011 | EP2285381A2 Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same |
| 02/23/2011 | EP2285380A1 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
| 02/23/2011 | EP2285379A1 1-methylnicotinamide analogs |
| 02/23/2011 | EP2285378A1 Treatment for ocular-related disorders |
| 02/23/2011 | EP2285377A1 Method for treating cognitive deficits |
| 02/23/2011 | EP2285376A1 6-aminonicotinamide derivatives as potent and selective histone deacetylase inhibitors |
| 02/23/2011 | EP2285375A2 Spiroazaindoles |
| 02/23/2011 | EP2285374A1 Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| 02/23/2011 | EP2285373A2 Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| 02/23/2011 | EP2285372A2 Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| 02/23/2011 | EP2285371A2 Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds |
| 02/23/2011 | EP2285370A1 Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder. |
| 02/23/2011 | EP2285369A2 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 02/23/2011 | EP2285368A2 New Use |
| 02/23/2011 | EP2285367A1 Pharmaceutical compositions for the treatment of warts |
| 02/23/2011 | EP2285366A2 Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules |
| 02/23/2011 | EP2285365A1 Use of a composition comprising at least one beta-blocker for the treatment of sleep disorders |
| 02/23/2011 | EP2285364A2 Therapeutic replenishment and enrichment of ocular surface lubrication |
| 02/23/2011 | EP2285363A2 Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| 02/23/2011 | EP2285359A2 Solid pharmaceutical formulation with delayed release |
| 02/23/2011 | EP2285358A1 Pulsatile release of valsartan |
| 02/23/2011 | EP2285357A1 Pharmaceutical compositions comprising brivaracetam |
| 02/23/2011 | EP2285356A2 Process for preparing a tablet comprising metformin |
| 02/23/2011 | EP2285353A1 Modified release formulations of hmg coa reductase inhibitors |
| 02/23/2011 | EP2285352A2 Atorvastatin compositions |
| 02/23/2011 | EP2285351A2 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas |
| 02/23/2011 | EP2285348A1 Opioid composition for treating skin lesions |
| 02/23/2011 | EP2285346A1 Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics |
| 02/23/2011 | EP2285345A1 Pulmonary delivery of a fluoroquinolone |
| 02/23/2011 | EP2285244A1 Sialic acid to support the immune system in the elderly |
| 02/23/2011 | EP2285242A2 Plant extract and pufa combinations |
| 02/23/2011 | EP2285219A1 Controlled release formulations of alprazolam |
| 02/23/2011 | EP2285218A2 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| 02/23/2011 | EP2285217A1 Compounds for improving learning and memory |
| 02/23/2011 | EP2285216A1 Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| 02/23/2011 | EP2285215A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 02/23/2011 | EP2285214A1 Rasagiline soft gelatin capsules |
| 02/23/2011 | EP2197456B1 Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid |
| 02/23/2011 | EP2155731B1 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
| 02/23/2011 | EP2155721B1 Organic compounds |
| 02/23/2011 | EP2085076B1 Pharmaceutical composition in the form of coated microspheres for the modified release of a muscle relaxant and an nsaid |
| 02/23/2011 | EP2080514B1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 02/23/2011 | EP2066638B1 Process for the purification of montelukast |
| 02/23/2011 | EP2027123B1 Compounds and compositions as protein kinase inhibitors |
| 02/23/2011 | EP2027104B1 Arylsulfonylchromans as 5-ht6 inhibitors |
| 02/23/2011 | EP2010181B1 Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
| 02/23/2011 | EP1962843B1 Use of parp-1 inhibitors |
| 02/23/2011 | EP1928492B1 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| 02/23/2011 | EP1919910B1 Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
| 02/23/2011 | EP1919907B1 Heterocyclic compound |
| 02/23/2011 | EP1919905B1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
| 02/23/2011 | EP1885707B1 A process for the purification of 10-deacetylbaccatine iii from 10-de acet yl-2- debenzoyl-2-pentenoylbaccatine iii |
| 02/23/2011 | EP1844028B1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF |
| 02/23/2011 | EP1819353B1 Composition for proteasome inhibition |
| 02/23/2011 | EP1812388B1 Sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 02/23/2011 | EP1805164B1 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| 02/23/2011 | EP1799306B1 Compositions and methods for treating cognitive disorders |
| 02/23/2011 | EP1765358B1 Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones |
| 02/23/2011 | EP1765342B9 Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for the preparation thereof |
| 02/23/2011 | EP1740599B1 Anthracycline derivatives |
| 02/23/2011 | EP1737843B1 Inhibitors of akt activity |
| 02/23/2011 | EP1737451B1 Monocyclic heterocycles as kinase inhibitors |
| 02/23/2011 | EP1697360B1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo 1, 2-a pyridine-6-carboxamide mesylate salt. |
| 02/23/2011 | EP1697347B1 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication |
| 02/23/2011 | EP1682520B1 Amide derivatives |
| 02/23/2011 | EP1677774B1 Citicoline-based composition in combination with vitamins for the prevention and treatment of eye pathologies |
| 02/23/2011 | EP1656358B1 Stable polymorph of bifeprunox mesilate |
| 02/23/2011 | EP1654263B2 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 02/23/2011 | EP1643985B1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 02/23/2011 | EP1634589B1 Aqueous olanexidine solution, method of preparing the same, and disinfectant |
| 02/23/2011 | EP1617218B1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR |
| 02/23/2011 | EP1610791B1 Implantable polymeric device for sustained release of dopamine agonist |
| 02/23/2011 | EP1556025B1 Compositions comprising vitamin k for preventing hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease by preventing age-related stiffening of arteries |
| 02/23/2011 | EP1505989B1 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| 02/23/2011 | EP1487810B9 4-(diarylmethyl)-1-piperazinyl derivatives |
| 02/23/2011 | EP1448550B1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 02/23/2011 | EP1409461B1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 02/23/2011 | EP1268096B2 Extrusion die |
| 02/23/2011 | EP1227805B2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/23/2011 | EP1144459B2 Cross-linked hyaluronic acids and medical uses thereof |
| 02/23/2011 | EP1135504B1 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 02/23/2011 | EP1113819B1 Antibody directed enzyme prodrug therapy (adept) with glucuronidase |
| 02/23/2011 | EP1070725B9 Solid dispersion containing sialic acid derivative |
| 02/23/2011 | EP1000023B1 Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
| 02/23/2011 | EP0947500B1 Sulfonamide derivatives and drugs containing the same as the active ingredient |
| 02/23/2011 | CN1989108B Method for producing carbostyryl compound |
| 02/23/2011 | CN1980664B CRTH2 receptor ligands for therapeutic use |
| 02/23/2011 | CN1946725B Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 02/23/2011 | CN1942466B Caspase inhibitors and uses thereof |
| 02/23/2011 | CN1882549B 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 02/23/2011 | CN1751042B Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |